Abstract
Many chronic inflammatory diseases are associated with deregulated intracellular signal transduction pathways. Resultant pathogenic interactions between immune and stromal cells lead to changes in cell activation, proliferation, migratory capacity, and cell survival that all contribute to inflammation. Increasing efforts are now being made in the design of novel therapeutic compounds to interfere with signaling pathways in inflammatory diseases like rheumatoid arthritis (RA). In this review we will outline the major signal transduction pathways involved in the pathogenesis of RA. We will assess advances in targeting a number of key intracellular pathways, including nuclear factor-κB (NF-κB), mitogen-associated protein kinases (MAPKs), phosphoinositide 3-kinase (PI3K) / Akt, signal transducers and activators of transcription (STATs), and reactive oxygen species (ROS) production. Finally, we will discuss recently identified lead molecules and the progress of selected compounds towards becoming new drugs for the treatment of inflammatory diseases.
Keywords: inflammatory disease, rheumatoid arthritis, signal transduction, nuclear factor, mitogen-activated protein kinase, reactive oxygen species, novel therapies
Current Pharmaceutical Design
Title: Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy
Volume: 11 Issue: 5
Author(s): Sander W. Tas, Philip H.J. Remans, Kris A. Reedquist and Paul P. Tak
Affiliation:
Keywords: inflammatory disease, rheumatoid arthritis, signal transduction, nuclear factor, mitogen-activated protein kinase, reactive oxygen species, novel therapies
Abstract: Many chronic inflammatory diseases are associated with deregulated intracellular signal transduction pathways. Resultant pathogenic interactions between immune and stromal cells lead to changes in cell activation, proliferation, migratory capacity, and cell survival that all contribute to inflammation. Increasing efforts are now being made in the design of novel therapeutic compounds to interfere with signaling pathways in inflammatory diseases like rheumatoid arthritis (RA). In this review we will outline the major signal transduction pathways involved in the pathogenesis of RA. We will assess advances in targeting a number of key intracellular pathways, including nuclear factor-κB (NF-κB), mitogen-associated protein kinases (MAPKs), phosphoinositide 3-kinase (PI3K) / Akt, signal transducers and activators of transcription (STATs), and reactive oxygen species (ROS) production. Finally, we will discuss recently identified lead molecules and the progress of selected compounds towards becoming new drugs for the treatment of inflammatory diseases.
Export Options
About this article
Cite this article as:
Tas W. Sander, Remans H.J. Philip, Reedquist A. Kris and Tak P. Paul, Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy, Current Pharmaceutical Design 2005; 11 (5) . https://dx.doi.org/10.2174/1381612053381918
DOI https://dx.doi.org/10.2174/1381612053381918 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lifestyle Modification in Rheumatoid Arthritis: Dietary and Physical Activity Recommendations Based on Evidence
Current Rheumatology Reviews Psychosomatic Features, Compliance and Complementary Therapies in Rheumatoid Arthritis
Current Rheumatology Reviews ADAM8 in Allergy
Inflammation & Allergy - Drug Targets (Discontinued) Modifying Toll-like Receptor 9 Signaling for Therapeutic Use
Mini-Reviews in Medicinal Chemistry Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design p38 Mitogen-Activated Protein Kinase (MAPK) in Rheumatoid Arthritis
Mini-Reviews in Medicinal Chemistry Humoral Immunity Against HDL Particle: A New Perspective in Cardiovascular Diseases?
Current Pharmaceutical Design Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Second Messenger Modulation: A Novel Target of Future Antidepressants?
Current Medicinal Chemistry Blood Coagulation as an Intrinsic Pathway for Proinflammation: A Mini Review
Inflammation & Allergy - Drug Targets (Discontinued) Volatile Disease Biomarkers in Breath: A Critique
Current Pharmaceutical Biotechnology Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists
Current Medicinal Chemistry Alterations in the Vascular Reactivity of Aorta in the Early and Late Phase of Adjuvant-Induced Arthritis in Rat
Vascular Disease Prevention (Discontinued) Interstitial Lung Disease in Sjogrens Syndrome
Current Rheumatology Reviews Phospholipid/Bile Salt Based Novel Mixed Nanomicelles of Methotrexate Co-encapsulated with Sesamol: Preparation, Characterization, and Evaluation of Antiradical Effects In Vitro
Current Nanomedicine Spectroscopic Studies of the Effects of Glycation of Human Serum Albumin on L-Trp Binding
Protein & Peptide Letters Colony-Stimulating Factor-1 Receptor Inhibitors for the Treatment of Cancer and Inflammatory Disease
Current Topics in Medicinal Chemistry The Effect of Statin Therapy on Arterial Stiffness by Measuring Pulse Wave Velocity: A Systematic Review
Current Vascular Pharmacology Modulation of Cardiovascular Function by Adipokines
Cardiovascular & Hematological Disorders-Drug Targets B-Lymphocytes Govern the Pathogenesis of Sjogren's Syndrome
Current Pharmaceutical Biotechnology